Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review

Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cardiff Oncology Inc (Cardiff Oncology), formerly Trovagene Inc is a clinical-stage biotechnology company that focuses on developing drugs which target cell division (mitosis) using precision cancer medicine (PCM) approach for the treatment of hematologic and solid tumor cancers. The company lead product candidate is Onvansertib (previously known as PCM-075), an oral and adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1) enzyme. It is being developed in combination with chemotherapies and targeted therapeutics for treatment of relapsed/refractory acute myeloid leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and second-line KRAS mutation-metastatic Colorectal Cancer (mCRC). Onvansertib is being evaluated in three clinical trials, namely, TROV-052, TROV-053 and TROV-054. Cardiff Oncology is headquartered in San Diego, California, the US.

Cardiff Oncology Inc Key Recent Developments

Aug 11,2020: Cardiff Oncology announces second quarter 2020 results and highlights
Jun 18,2020: Cardiff Oncology: Appointment of chief executive officer
May 07,2020: Trovagene announces first quarter 2020 results and highlights
May 06,2020: Trovagene announces changing of company name to Cardiff Oncology and appointment of Mark Erlander, PhD, as Chief Executive Officer
Apr 22,2020: Trovagene expands board with addition of three industry leaders - James Armitage, MD, Lale White, and Gary Pace, PhD

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Section 1 - About the Company
Cardiff Oncology Inc - Key Facts
Cardiff Oncology Inc - Key Employees
Cardiff Oncology Inc - Key Employee Biographies
Cardiff Oncology Inc - Major Products and Services
Cardiff Oncology Inc - History
Cardiff Oncology Inc - Company Statement
Cardiff Oncology Inc - Locations And Subsidiaries
Head Office
Section 2 Company Analysis
Company Overview
Cardiff Oncology Inc - Business Description
Business Segment: Royalties
Performance
Business Segment: Service
Performance
Cardiff Oncology Inc - Corporate Strategy
Cardiff Oncology Inc - SWOT Analysis
SWOT Analysis - Overview
Cardiff Oncology Inc - Strengths
Cardiff Oncology Inc - Weaknesses
Cardiff Oncology Inc - Opportunities
Cardiff Oncology Inc - Threats
Cardiff Oncology Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Cardiff Oncology Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Aug 11, 2020: Cardiff Oncology announces second quarter 2020 results and highlights
Jun 18, 2020: Cardiff Oncology: Appointment of chief executive officer
May 07, 2020: Trovagene announces first quarter 2020 results and highlights
May 06, 2020: Trovagene announces changing of company name to Cardiff Oncology and appointment of Mark Erlander, PhD, as Chief Executive Officer
Apr 22, 2020: Trovagene expands board with addition of three industry leaders - James Armitage, MD, Lale White, and Gary Pace, PhD
Apr 15, 2020: Trovagene granted loan from JPMorgan Chase Bank
Apr 15, 2020: Trovagene receives loan under Paycheck Protection Program
Mar 05, 2020: Trovagene announces three new nominees for election to board of directors
Nov 07, 2019: Trovagene announces third quarter 2019 results and highlights
Aug 08, 2019: Trovagene announces second quarter 2019 results and highlights
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Cardiff Oncology Inc, Key Facts
Cardiff Oncology Inc, Key Employees
Cardiff Oncology Inc, Key Employee Biographies
Cardiff Oncology Inc, Major Products and Services
Cardiff Oncology Inc, History
Cardiff Oncology Inc, Key Competitors
Cardiff Oncology Inc, Ratios based on current share price
Cardiff Oncology Inc, Annual Ratios
Cardiff Oncology Inc, Annual Ratios (Cont...1)
Cardiff Oncology Inc, Interim Ratios
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Cardiff Oncology Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Cardiff Oncology Inc, Performance Chart (2015 - 2019)
Cardiff Oncology Inc, Ratio Charts
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cardiff Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review

Cardiff Oncology Inc (CRDF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

The Cardiff Property plc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

The Cardiff Property plc Company Profile is a detailed strategic and analytical report on The Cardiff Property plc. The 2018 version of the report offers detailed insights into the companys

USD 200 View Report

AVEO Oncology Inc (AVEO) - Financial and Strategic SWOT Analysis Review

AVEO Oncology Inc (AVEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Gritstone Oncology Inc (GRTS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Gritstone Oncology Inc (Gritstone) develops and commercialize tumor-specific cancer immunotherapies. The companys pipeline product portfolio comprises GRANITE-001, for solid tumors, including metastatic non-small cell lung cancer and gastroesophageal, bladder and

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available